MEDINCELL Stock Advances 6.52% Over the Week Amid Market Downturn

MEDINCELL's stock closed the week at 27.44 euros, marking a 6.52% increase from the previous Friday. This performance goes against the trend of the French indices, with the CAC 40 and the SBF 120 both declining by 1.72% and 1.75% respectively over the same period. Trading intensified at the end of the week, with a volume of 235,274 shares traded on Friday, more than double the average observed on previous days. The price reached a high of 28.64 euros on Thursday before slightly retracting at the weekly close. Over a broader timeline, the stock shows a remarkable increase of 80.29% over one year and 72.58% over three months, significantly outperforming the CAC 40 (+4.73% over one year).
This recent development comes in a favorable context for the Montpellier-based company. On Friday, October 10, the U.S. Food and Drug Administration (FDA) expanded the indication of UZEDY, the injectable treatment developed in partnership with Teva, to include bipolar I disorder in adults. This approval adds to the initial indication for schizophrenia obtained in 2023. UZEDY, which is based on MEDINCELL's SteadyTeq technology, has already been a significant commercial success with $95 million in sales recorded in the first half of 2025, following $117 million in the year 2024. The company receives royalties from these sales, which have quadrupled over the last fiscal year.

From a technical perspective, the stock is now very close to its weekly resistance level at 28.64 euros, which was reached on Thursday before the retreat on Friday. This zone represents a significant psychological threshold, tested during the session but not sustainably breached. The moving averages illustrate the ongoing upward momentum: the price is well above its 50-day average at 19.83 euros, and its 200-day average at 16.52 euros, confirming a firmly established upward trend. The increasing gap between these two averages, which has gradually widened in recent weeks, indicates an acceleration of the bullish movement.
The Bollinger Bands, which frame price fluctuations between 18.22 euros and 29.35 euros, show that the stock is operating in the upper part of its channel, a sign of sustained buying pressure. The MACD, a momentum indicator comparing two exponential moving averages, displays a line at 2.38 with a positive histogram at 0.37, confirming the continuation of the bullish dynamic in the short term. Additionally, the positive Chaikin Money Flow at 0.14 indicates that buying flows remain dominant despite the retreat on Friday. This technical configuration suggests that the stock maintains a favorable orientation, although the proximity of the resistance at 28.64 euros may temporarily hinder progress.